About Ocata Therapeutics (NASDAQ:OCAT)
Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: N/A
- Symbol: NASDAQ:OCAT
- Previous Symbol: OTCMKTS:ACTC
- CUSIP: N/A
- Web: www.ocata.com
- Trailing EPS: ($0.70)
- Net Margins: -4,564.66%
- Return on Equity: -103.02%
- Return on Assets: -46.18%
- Outstanding Shares: 42,230,000
Frequently Asked Questions for Ocata Therapeutics (NASDAQ:OCAT)
What is Ocata Therapeutics' stock symbol?
Ocata Therapeutics trades on the NASDAQ under the ticker symbol "OCAT."
How were Ocata Therapeutics' earnings last quarter?
Ocata Therapeutics Inc (NASDAQ:OCAT) posted its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.01. The biotechnology company earned $0.04 million during the quarter. Ocata Therapeutics had a negative return on equity of 103.02% and a negative net margin of 4,564.66%. View Ocata Therapeutics' Earnings History.
Who are some of Ocata Therapeutics' key competitors?
Some companies that are related to Ocata Therapeutics include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Medivation (MDVN), Kite Pharma (KITE), Exelixis (EXEL), bluebird bio (BLUE), Juno Therapeutics (JUNO), Neurocrine Biosciences (NBIX), Bioverativ (BIVV), Shire-Nps Pharmaceuticals (NPSP), TESARO (TSRO), BeiGene (BGNE), Sarepta Therapeutics (SRPT), Auspex Pharmaceuticals (ASPX), AveXis (AVXS), Clovis Oncology (CLVS) and GW Pharmaceuticals PLC (GWPH).
How do I buy Ocata Therapeutics stock?
Shares of Ocata Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ocata Therapeutics' stock price today?
One share of Ocata Therapeutics stock can currently be purchased for approximately $8.47.
How can I contact Ocata Therapeutics?
Ocata Therapeutics' mailing address is 33 Locke Dr, MARLBOROUGH, MA 01752-1167, United States. The biotechnology company can be reached via phone at +1-508-7561212.
MarketBeat Community Rating for Ocata Therapeutics (NASDAQ OCAT)MarketBeat's community ratings are surveys of what our community members think about Ocata Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Ocata Therapeutics (NASDAQ:OCAT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Ocata Therapeutics (NASDAQ:OCAT)
Analysts' Ratings History for Ocata Therapeutics (NASDAQ:OCAT)
(Data available from 11/20/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|2/23/2016||Cantor Fitzgerald||Reiterated Rating||Hold||$8.50||N/A|
Earnings History and Estimates Chart for Ocata Therapeutics (NASDAQ:OCAT)
Earnings History by Quarter for Ocata Therapeutics (NASDAQ OCAT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Ocata Therapeutics (NASDAQ:OCAT)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Ocata Therapeutics (NASDAQ:OCAT)
No dividend announcements for this company have been tracked by MarketBeat.com
Latest Headlines for Ocata Therapeutics (NASDAQ OCAT)
Financials are not available for this stock.
Ocata Therapeutics (NASDAQ OCAT) Chart for Monday, November, 20, 2017